Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab in Platinum-Refractory SCCHN
NCT00382031Phase 3Completed
- Sponsor
- Genmab
- Start
- Nov 2006
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Zalutumumab + BSC with Best Supportive Care (2 arms). Primary endpoint: Overall Survival at 41 months. Started Nov 2006; status: completed.
02
Drugs
zalutumumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00382031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382031.